Cite
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
MLA
Michael Krams, et al. “Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism.” Movement Disorders, vol. 23, Oct. 2008, pp. 1860–66. EBSCOhost, https://doi.org/10.1002/mds.22169.
APA
Michael Krams, Jaren W. Landen, Steven A. Gunzler, Trish Kirchhoff, Penelope Hogarth, Jerry Weaver, Brenda D. Jamerson, Frank S. Menniti, & John G. Nutt. (2008). Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism. Movement Disorders, 23, 1860–1866. https://doi.org/10.1002/mds.22169
Chicago
Michael Krams, Jaren W. Landen, Steven A. Gunzler, Trish Kirchhoff, Penelope Hogarth, Jerry Weaver, Brenda D. Jamerson, Frank S. Menniti, and John G. Nutt. 2008. “Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism.” Movement Disorders 23 (October): 1860–66. doi:10.1002/mds.22169.